Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Ravulizumab

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Xencor Extends US Patent Term For Specific Xtend Antibodies
    Xencor Extends US Patent Term For Specific Xtend Antibodies

    09 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251209345770/en/Xencor-Announces-Extension-of-U.S.-Patent-Term-on-Certain-Xtend-Antibodies

    BUSINESSWIRE
    09 Dec 2025
    Share Share
    Alexion’s Biologics Ultomiris Receives Suppl Approval in US
    Alexion’s Biologics Ultomiris Receives Suppl Approval in US

    27 Jun 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761108

    FDA
    27 Jun 2025
    Share Share
    AZ touts Ultomiris Results in Post-Transplant Complication Trial
    AZ touts Ultomiris Results in Post-Transplant Complication Trial

    17 Jun 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/az-touts-early-ultomiris-survival-data-kids-living-rare-post-transplant-complication

    FIERCE PHARMA
    17 Jun 2025
    Share Share
    Novartis Fabhalta Improves Hemoglobin in PNH Patients from Anti-C5
    Novartis Fabhalta Improves Hemoglobin in PNH Patients from Anti-C5

    04 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/06/2992829/0/en/New-Phase-IIIB-data-shows-Novartis-Fabhalta-improved-hemoglobin-levels-in-adult-patients-with-paroxysmal-nocturnal-hemoglobinuria-who-switched-from-anti-C5-therapy.html

    GLOBENEWSWIRE
    04 Dec 2024
    Share Share
    Alexion`s Biologic Ultomiris (Ravulizumab) Receives Suppl Approval in US
    Alexion`s Biologic Ultomiris (Ravulizumab) Receives Suppl Approval in US

    19 Sep 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761108

    FDA
    19 Sep 2024
    Share Share
    Alexion's Biologic Ultomiris (ravulizumab-cwvz) Receives Approvals in the US
    Alexion's Biologic Ultomiris (ravulizumab-cwvz) Receives Approvals in the US

    28 Jun 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761108

    FDA
    28 Jun 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.